MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.

Nicolo' Gebbia, Giuseppe Badalamenti, Lorena Incorvaia, Giovam Battista Rini, Gaetano Leto, Lorena Incorvaia, Danilo Di Trapani, Giuseppe Badalamenti, Nicola Gebbia, Giovambattista Rini, Giovambattista Rini, Carlo Arcara, Carmela Sferrazza, Salvatore Fricano, Gaetano Leto, Carmela Sferrazza, Carmelo Carlo Arcara

Risultato della ricerca: Article

60 Citazioni (Scopus)

Abstract

Background: The clinical significance of thecirculating levels of activin A and matrix metalloproteinase-2(MMP-2) and -9 (MMP-9) was investigated in patients withbreast cancer (BC) or prostate cancer (PC) with (M1) orwithout (M0) bone metastasis. Patients and Methods: MMP-2,MMP-9 and activin A blood concentrations were measured byenzyme immunoassays in 79 cancer patients and in 57 healthyblood donors (HS) who served as a control group. Thediagnostic accuracy of these molecules to discriminate betweenM0 and M1 patients was evaluated by the receiver operatingcharacteristic curve (ROC) and compared to that of tumormarkers CA15.3 or prostate-specific antigen (PSA). Results:Activin A and MMP-2 were significantly increased in BC andPC patients as compared to sex-matched HS while MMP-9levels were more elevated only in the PC patients. Interestingly,in the PC patients, activin A levels were significantly higher thanthose measured in the BC patients. In this latter group, activin Aand CA15.3 but not MMP-2 or MMP-9 were increased in theM1 patients as compared to M0 patients. Furthermore, asignificant relationship was also highlighted between activin Aconcentration and the number of bone metastases and tumorgrade, between MMP-9 and tumor grade, and between MMP-2and CA15.3. ROC curve analysis showed a good diagnosticaccuracy for activin A and CA15.3 but a poor accuracy forMMP-2 and MMP-9 in discriminating between M0 and M1patients. However, CA15.3 retained the best diagnostic accuracyin this respect. In the PC group, only activin A and PSA levelswere significantly increased in the M1 patients as compared tothe M0 patients. A similar although not statistically significanttrend was noted for MMP-9. Interestingly, a significant correlationwas observed between PSA and activin A and MMP-9, andbetween Activin A and Gleason score and the number ofskeletal metastases. ROC curve analysis showed a gooddiagnostic accuracy for activin A, MMP-9 and PSA and a poordiagnostic accuracy for MMP-2 in detecting M1 patients.However, PSA showed the highest diagnostic accuracy.Conclusion: Activin A, MMP-2 and MMP-9 may be regarded aspossible therapeutic targets in the treatment of metastatic bonedisease. However, their usefulness as additional markers of bonemetastasis remains to be better defined
Lingua originaleEnglish
pagine (da-a)1519-1525
Numero di pagine7
RivistaAnticancer Research
Volume27
Stato di pubblicazionePublished - 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.'. Insieme formano una fingerprint unica.

  • Cita questo

    Gebbia, N., Badalamenti, G., Incorvaia, L., Rini, G. B., Leto, G., Incorvaia, L., Di Trapani, D., Badalamenti, G., Gebbia, N., Rini, G., Rini, G., Arcara, C., Sferrazza, C., Fricano, S., Leto, G., Sferrazza, C., & Arcara, C. C. (2007). MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Research, 27, 1519-1525.